AU2021298661A1 - Biomarker combinations for determining aggressive prostate cancer - Google Patents

Biomarker combinations for determining aggressive prostate cancer Download PDF

Info

Publication number
AU2021298661A1
AU2021298661A1 AU2021298661A AU2021298661A AU2021298661A1 AU 2021298661 A1 AU2021298661 A1 AU 2021298661A1 AU 2021298661 A AU2021298661 A AU 2021298661A AU 2021298661 A AU2021298661 A AU 2021298661A AU 2021298661 A1 AU2021298661 A1 AU 2021298661A1
Authority
AU
Australia
Prior art keywords
aggressive
population
psa
analyte
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021298661A
Other languages
English (en)
Inventor
Douglas Campbell
Thao Ho Le
Yanling Lu
Bradley Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minomic International Ltd
Original Assignee
Minomic International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902212A external-priority patent/AU2020902212A0/en
Application filed by Minomic International Ltd filed Critical Minomic International Ltd
Publication of AU2021298661A1 publication Critical patent/AU2021298661A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2021298661A 2020-06-30 2021-06-30 Biomarker combinations for determining aggressive prostate cancer Pending AU2021298661A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902212A AU2020902212A0 (en) 2020-06-30 Biomarker combinations for determining aggressive prostate cancer
AU2020902212 2020-06-30
PCT/AU2021/050705 WO2022000041A1 (en) 2020-06-30 2021-06-30 Biomarker combinations for determining aggressive prostate cancer

Publications (1)

Publication Number Publication Date
AU2021298661A1 true AU2021298661A1 (en) 2023-02-02

Family

ID=79317588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021298661A Pending AU2021298661A1 (en) 2020-06-30 2021-06-30 Biomarker combinations for determining aggressive prostate cancer

Country Status (6)

Country Link
US (1) US20230305009A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172629A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023531567A (cg-RX-API-DMAC7.html)
AU (1) AU2021298661A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188184A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022000041A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023366061A1 (en) * 2022-10-20 2025-05-29 Minomic International Ltd. Methods for detecting aggressive prostate cancer
CN121101470B (zh) * 2025-09-08 2026-05-12 简勇 一种癌症危险程度辨别方法和系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035766A2 (en) * 2005-09-19 2007-03-29 The Johns Hopkins University Biomarker for prostate cancer
CA3011988A1 (en) * 2016-01-22 2017-07-27 Otraces Inc. Systems and methods for improving disease diagnosis
JP7240674B2 (ja) * 2017-09-29 2023-03-16 Ｍｇｃウッドケム株式会社 前立腺癌の検出方法
EP3861348A4 (en) * 2018-10-05 2022-07-20 Minomic International Ltd. BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER

Also Published As

Publication number Publication date
JP2023531567A (ja) 2023-07-24
EP4172629A1 (en) 2023-05-03
US20230305009A1 (en) 2023-09-28
EP4172629A4 (en) 2024-07-10
CA3188184A1 (en) 2022-01-06
WO2022000041A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US12618843B2 (en) Biomarker combinations for determining aggressive prostate cancer
CA2516795C (en) Circulating tumor cells (ctc's): early assessment of time to progression,_survival and response to therapy in metastatic cancer patients
Lopes et al. Thyroid cancer and thyroid autoimmune disease: A review of molecular aspects and clinical outcomes
TWI698639B (zh) 前列腺抗原標準品及其用途
CN107422127A (zh) 用非稀有细胞检测稀有细胞的方法
US20230305009A1 (en) Biomarker combinations for determining aggressive prostate cancer
AU2016297676B2 (en) Biomarker combinations for prostate disease
Sotome et al. Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)− breast cancer
US20190361027A1 (en) Methods for determining breast cancer risk
Partyka et al. A comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification
US20250012804A1 (en) Use of microvesicles for benign colorectal polyps and colorectal cancer screening
US11791043B2 (en) Methods of prognosing early stage breast lesions
EP4605753A1 (en) Methods for detecting aggressive prostate cancer
US20230176061A1 (en) Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers
HK1250257B (en) Biomarker combinations for prostate disease
WO2025049926A1 (en) Methods of selecting treatment options for cancer